Amplo Biotechnology, Inc.
Publicly observedTowson, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Towson | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Amplo Biotechnology, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | H93DMA2RBMS1 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Jun 2023Publicly observed
NIH SBIR/STTR award: Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
USD 1,357,367.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2023Publicly observed
NIH SBIR/STTR award: Targeted ColQ gene therapy for Congenital Myasthenic Syndromes
USD 601,044.00 · National Institute of Neurological Disorders and Stroke · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.